The association between lipid-lowering drugs and circulating concentration of PCSK9

Abstract

Get full access to this article

View all access options for this article.

References

Catapano

Graham

De Backer

et al.

2016 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; 37: 2999–3058.

Reiner

. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol 2013; 10: 453–464.

Pećin

Hartgers

Hovingh

et al.

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol 2017; 24: 1383–1401.

Reiner

. PCSK9 inhibitors-past, present and future. Expert Opin Drug Metab Toxicol 2015; 11: 1517–1521.

Reiner

Laufs

Cosentino

et al.

The year in cardiology 2018: prevention. Eur Heart J 2019; 40: 336–344.

Nozue

. Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb 2017; 24: 895–907.

Macchi

Banach

Corsini

et al.

Changes in circulating PCSK9 levels – experimental and clinical approaches with lipid lowering agents. Eur J Prevent Cardiol. 2019; 26: 928–929.

Welder

Zineh

Pacanowski

et al.

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51: 2714–2721.

Vlachopoulos

Terentes-Printzios

Georgiopoulos

et al.

Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: a systematic review and meta-analysis. Atherosclerosis 2016; 252: 50–60.

10.

El Khoury

Roussel

Fumeron

et al.

Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes Obes Metab 2018; 20: 943–953.